Abstract
AbstractThirteen percent of the Danish population are treated with a statin—half of these are in primary prevention, and most are > 65 years old. Statins have known muscular side effects (i.e., myalgia) correlated to reduced muscle performance. This study examines if years of statin treatment in older people introduce subclinical muscle discomfort and loss of muscle mass and strength. In total, 98 participants (71.1 ± 3.6 years (mean ± SD)), who were in primary prevention treatment for elevated plasma cholesterol with a statin, were included in this study. Statin treatment was discontinued for 2 months and then re-introduced for 2 months. Primary outcomes included muscle performance and myalgia. Secondary outcomes included lean mass and plasma cholesterol. Functional muscle capacity measured as a 6-min walk test increased after discontinuation (from 542 ± 88 to 555 ± 91 m, P < 0.05) and remained increased after re-introduction (557 ± 94 m). Similar significant results were found with a chair stand test (15.7 ± 4.3 to 16.3 ± 4.9 repetitions/30 s) and a quadriceps muscle test. Muscle discomfort during rest did not change significantly with discontinuation (visual analog scale from 0.9 ± 1.7 to 0.6 ± 1.4) but increased (P < 0.05) with the re-introduction (to 1.2 ± 2.0) and muscle discomfort during activity decreased (P < 0.05) with discontinuation (from 2.5 ± 2.6 to 1.9 ± 2.3). After 2 weeks of discontinuation, low-density lipoprotein cholesterol increased from 2.2 ± 0.5 to 3.9 ± 0.8 mM and remained elevated until the re-introduction of statins (P < 0.05). Significant and lasting improvements in muscle performance and myalgia were found at the discontinuation and re-introduction of statins. The results indicate a possible statin-related loss of muscle performance in older persons that needs further examination.
Funder
Royal Library, Copenhagen University Library
Publisher
Springer Science and Business Media LLC
Subject
Geriatrics and Gerontology,Aging
Reference50 articles.
1. Mitka M. Expanding statin use to help more at-risk patients is causing financial heartburn. JAMA. 2003;290(17):2243.
2. Hales CM, Servais J, Martin CB, and Kohen D. Prescription drug use among adults aged 40–79 in the United States and Canada. NCHS Data Brief No. 347, August 2019. Available from: https://www.cdc.gov/nchs/products/databriefs/db347.htm.
3. Guadamuz JS, Shooshtari A, Qato DM. Global, regional and national trends in statin utilisation in high-income and low/middle-income countries, 2015–2020. BMJ Open. 2022;12(9):e061350.
4. The Danish Health Data Authority. www.medstat.dk [Internet]. Accessed 3 March 2023.
5. Engebretsen I, Munkhaugen J, Bugge C, Halvorsen S, Ødegaard KM, Støvring H, et al. Gaps and discontinuation of statin treatment in Norway: potential for optimizing management of lipid lowering drugs. Eur Heart J Open. 2022;2(6):oeac070.
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献